ArticleNature communications2025
Regional and cell specific bioactivity of injectable extracellular matrix biomaterials in myocardial infarction.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Myocardial infarction treatment with a composite hydrogel containing metformin-induced vesicles of adipose-derived stem cells.Materials today. Bio · 2026Article
- Infusible Extracellular Matrix Biomaterial Enhances Cell-Specific Pro-Repair Responses Following Acute Myocardial Infarction.Advanced healthcare materials · 2026Article
- Review
- A 3-Dimensional Bioprinted Decellularized Umbilical Cord Matrix Patch for Enhanced Storage and Delivery of Extracellular Vesicles in Diabetic Wound Healing.Research (Washington, D.C.) · 2026Article
- Integrated spatial transcriptomics and single-cell RNA sequencing reveal Lars2-mediated spatiotemporal dynamics of myocardial remodeling in a mouse model of transverse aortic constriction.Frontiers in immunology · 2026Article
- Regional and cell specific bioactivity of injectable extracellular matrix biomaterials in myocardial infarction.Nature communications · 2025Article
Corrections and comments
- Update of
Authors and funding
19 authors.
Funding
Abstract
Myocardial infarction (MI) remains a global health concern. To mitigate subacute and chronic MI pathophysiology, we previously investigated a pro-reparative decellularized extracellular matrix hydrogel. Despite increasing interest in biomaterial scaffolds, single cell and spatially resolved transcriptomics have not been used to probe their therapeutic activity in the heart. Here, we utilize spatial transcriptomics and single nucleus RNA sequencing to delineate the regional and cell-specific bioactivity of extracellular matrix biomaterials. Extracellular matrix hydrogel subacute treatment in female rats induces cardiac resident macrophage preservation, fibroblast activation, and increased lymphatic, vasculature, smooth muscle, and cardiomyocyte development as well as neurogenesis. Chronic treatment in female rats elicits macrophage polarization, neurogenesis, and development of cardiomyocytes, endothelial cells, and fibroblasts. When comparing treatment timepoints, subacute administration has stronger immune modulation, while chronic administration demonstrates higher cardiac development markers. Both subacute and chronic administration are associated with fibroblast activation and vasculature development. Thus, we elucidate undiscovered therapeutic targets of an injectable extracellular matrix hydrogel, further demonstrating the potential of these biomaterials as an MI therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.